Project: First small molecule drug inhibitor of microRNAs: Treatment for systemic lupus erythematosus
| Acronym | BUTTERFLY (Reference Number: 12979) |
| Duration | 01/04/2019 - 03/04/2022 |
| Project Topic | BUTTERFLY will deliver a first-in-class drug for the treatment of systemic lupus erythematosus (SLE). The BUTTERFLY drug will inhibit miR-155, and will be the first small molecule drug that directly targets microRNAs. To do so, BUTTERFLY partners will implement a unique drug discovery platform for the cost- and time-efficient development of new drugs. By the end of BUTTERFLY, the lead drug will have been validated in animal models and will be ready to enter final regulatory preclinical testing. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 10 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Saverna Therpautics AG | Coordinator | Switzerland |
| 2 | SpiroChem AG | Partner | Switzerland |
| 3 | Redoxis AB | Partner | Sweden |